Lo Shih-Hsing, Liu Yi-Ching, Dai Zen-Kong, Chen I-Chen, Wu Yen-Hsien, Hsu Jong-Hau
Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Front Pediatr. 2021 Feb 25;9:639551. doi: 10.3389/fped.2021.639551. eCollection 2021.
Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a case of acute decompensated heart failure in chemotherapy-induced cardiomyopathy. This case suggests that in children with acute heart failure refractory to conventional medications, low dose of sacubitril/valsartan may be an effective therapy.
缬沙坦/沙库巴曲是一种新批准用于治疗成人慢性心力衰竭的药物，它是血管紧张素受体抑制剂和中性肽链内切酶抑制剂的组合。然而，缬沙坦/沙库巴曲在儿科患者中的益处尚不清楚。我们在此报告其在化疗诱导的心肌病所致急性失代偿性心力衰竭病例中的临床益处。该病例表明，对于常规药物治疗无效的急性心力衰竭儿童，低剂量的沙库巴曲/缬沙坦可能是一种有效的治疗方法。
